US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Militia Long/Short Equity ETF

29.28

-0.2200-0.75%

Volume:14.88K

Turnover:436.36K

Market Cap:- -

PE:- -

High:29.63

Open:29.33

Low:29.23

Close:29.50

Loading ...

Overview Company News Filings

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

HURA: Initiating an Immune Response

Zacks Small Cap Research

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Immutep Quarterly Activities Report Q2 FY25

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Press Release: Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Firstgroup and Virgin push back against state clampdown on open-access rail firms

FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":29.28,"timestamp":1751313600000,"preClose":29.5,"halted":0,"volume":14877,"delay":0,"floatShares":2870000,"shares":0,"eps":0,"marketStatus":"Post-Mkt","change":-0.22,"latestTime":"06-30 18:14:34 EDT","open":29.3301,"high":29.63,"low":29.23,"amount":436360.8937,"amplitude":0.013559,"askPrice":43.92,"askSize":200,"bidPrice":28.8,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1751328000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":29.5,"sharesOutstanding":2870000,"nav":29.02,"aum":83287400,"bidAskSpread":0,"volumeRatio":0.589426},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.589426,"shares":0,"dividePrice":0,"high":29.63,"amplitude":0.013559,"preClose":29.5,"low":29.23,"week52Low":25.63,"pbRate":"--","week52High":29.71,"institutionHeld":0,"latestPrice":29.28,"committee":-0.333333,"eps":0,"divideRate":0,"volume":14877,"delay":0,"ttmEps":0,"open":29.3301,"prevYearClose":25.88,"prevWeekClose":29.5,"prevMonthClose":28.1031,"prevQuarterClose":27.84,"fiveDayClose":28.7113,"twentyDayClose":28.1031,"sixtyDayClose":27.76},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508345850","title":"Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2508345850","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508345850?lang=en_us&edition=fundamental","pubTime":"2025-02-04 19:45","pubTimestamp":1738669500,"startTime":"0","endTime":"0","summary":"Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth. Excluding Contributions from Paxlovid and Comirnaty, Revenues Grew 12% Operationally. Full-Year 2024 Reported Diluted EPS of $1.41 and Adjusted Diluted EPS of $3.11. Fourth-Quarter 2024 Revenues of $17.8 Billion, Reflecting 21% Year-over-Year Operational Growth. Fourth-Quarter 2024 Reported Diluted EPS of $0.07 and Adjusted Diluted EPS of $0.63. On Track to Deliver Overall Net Cost Savings of Approximately $4.5 Billion by End of 2025 from Ongoing Cost Realignment Program. Reaffirms All Components of Full-Year 2025 Financial Guidance, including Revenues in a Range of $61.0 to $64.0 Billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00. NEW YORK, February 04, 2025----Pfizer Inc.  reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance provided on December 17, 2024.The fourth-quarter 2024 earnings presentation and accompanying prepared rema","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e75b2b7dcb07c669b5aa92e4e319edbe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-strong-full-2024-114500880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4592","LU0225284248.USD","IE00BLSP4452.SGD","LU1883839398.USD","LU0289739699.SGD","BK4568","BK4581","LU0306807586.USD","BCG","LU0321505868.SGD","EC","BK4139","BK4548","LU0122379950.USD","BK4599","LU0306806265.USD","QD","BK4166","OS","BK4533","SG9999002224.SGD","BK4535","BK4551","BK4503","LU1066051498.USD","BK4211","IE00B19Z3B42.SGD","MBC","BK4588","LU0170899867.USD","IE00BBT3K403.USD","LU0234572021.USD","BK4135","PFE","IE00BLSP4239.USD","LU0058720904.USD","SG9999001176.SGD","BK4201","LU0225771236.USD","LU1894683348.USD","BK4097","ORR","BK4195","SG9999002232.USD","SG9999001176.USD","LU0868494617.USD","BNTX","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2508638964","title":"HURA: Initiating an Immune Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2508638964","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508638964?lang=en_us&edition=fundamental","pubTime":"2025-02-04 17:16","pubTimestamp":1738660560,"startTime":"0","endTime":"0","summary":"IFx-2.0 is an intratumorally injected plasma DNA  that infects cancer cells to produce bacterial proteins on their surface. These proteins stimulate an innate immune response which destroys cancer cells and subsequently activates an adaptive immune response to overcome resistance. TuHURA has demonstrated safety and proof of concept in several small early-stage trials. To date, the company has completed four Phase I studies. They have shown an overall response rate  for MCC in many subjects. The dose escalation portion of the study established that IFx-2.0 was well-tolerated at all dose levels. Further study evaluated MCC patients who had previously received checkpoint therapy. Results showed that IFx-2.0 may overcome primary resistance to checkpoint inhibitor therapy and may provide support for administering the agent before checkpoint inhibitor therapy to increase response rates.Recent research has shown a correlation between high NPM1 mutations and VISTA expression, particularly in A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hura-initiating-immune-response-091600422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","BK4231","ORR","IP","IE00B66KJ199.SGD","HURA","ADC","BK4136","BK4080","BK4139","IE0031619046.USD","BK4588","CVR","CRS","BK4585","SPA","BK4161","LU2065731478.USD","IE00B19Z4B17.USD","LU2463526074.USD","BK4006"],"gpt_icon":0},{"id":"2507957937","title":"Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957937","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957937?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy. Datopotamab deruxtecan approved in the U.S. and Japan for same patient population. TOKYO & MUNICH, January 31, 2025----Datopotamab deruxtecan  has been recommended for approval in the European Union  for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 negative  breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.Datopotamab deruxtecan demonstrated a favorable safety profile over chemotherapy with no new safety concerns identified. Grade 3 or higher treatment-related adverse events  occurred in 21% and 45% of patients in the datopotamab deruxtecan and chemotherapy arms, respectively. The most common grade 3 or higher TRAEs were neutropenia , stomatitis , fatigue  and anemia . In the datopotamab de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-recommended-approval-eu-130000461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PR","HR","DSKYF","CR","ORR","BK4080","ADC","DSNKY","BK4007","BK4161","BK4195","BK4231","PBD","BK4211","BK4087","BK4203","CHMP","PFS","BK4213","BK4156","BK4225"],"gpt_icon":0},{"id":"2507957164","title":"Immutep Quarterly Activities Report Q2 FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957164","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957164?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer  received first regulatory approval. Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival  and 81.0% 24-month OS rate, significantly outperforming historical controls. Promising new results in first line head & neck cancer with PD-L1 CPS <1 reported at ESMO IO 2024, with median OS not reached and 67% 12-month OS rate well above historical controls. Phase II in soft tissue sarcoma shows three-fold increase in tumour hyalinization  compared to historical data from radiotherapy. Phase I trial of IMP761 reported favourable initial safety results advancing the first-in-class agonist LAG-3 antibody program. TACTI-004 – Start of Phase III Trial in 1L NSCLCIn December 2024, Immutep initiated its pivotal TACTI-004 Phase III clinical trial of eftilagimod alfa  for the treatment of first-line metastatic non-small cell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-quarterly-activities-report-q2-130000670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","BK4563","OS","IMM.AU","BK4211","IMMP","IO","ORR","INAQU","BK4139","BK4179","BK4097","PFS","CTOS","BK4104"],"gpt_icon":0},{"id":"2507659161","title":"Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2507659161","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507659161?lang=en_us&edition=fundamental","pubTime":"2025-01-30 01:37","pubTimestamp":1738172220,"startTime":"0","endTime":"0","summary":"These findings further reinforce the consistency of the BOT/BAL combination, which has already shown activity and a favorable safety profile across both multiple \"warm and cold\" tumor types, including colon cancer, lung cancer, melanoma and ovarian cancers.Patients with advanced sarcomas face poor outcomes and have limited treatment options, underscoring the urgent need for innovative therapies. This Phase 1 study evaluated the safety and efficacy of botensilimab , an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab , an anti-PD-1 antibody, in this challenging patient population.\"The publication in the Journal of Clinical Oncology further underscores the significant potential of botensilimab and balstilimab to address ‘cold’ tumors like certain subtypes of refractory sarcomas,\" said Dr. Breelyn A. Wilky, University of Colorado Cancer Center. \"These findings highlight the ability of this combination to deliver meaningful clinical benefits, including durable responses an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agenus-announces-publication-journal-clinical-173700119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRAE","LU0053666078.USD","ORR","BK4211","BK4107","PFS","BK4097","BK4195","AGEN","BK4139","BK4588","BAL","BK4585","L","OS"],"gpt_icon":0},{"id":"2507638975","title":"Press Release: Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258","url":"https://stock-news.laohu8.com/highlight/detail?id=2507638975","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507638975?lang=en_us&edition=fundamental","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory's TROP2 Antibody Drug Conjugate, OQY-3258. Companies also provide insights into proposed strategic merger. SAN MATEO, Calif., Jan. 29, 2025  -- Vincerx Pharma, Inc. , a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates  for the treatment of cancer, today highlighted Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, for patients with solid tumors. The companies also provided insights into their proposed strategic merger, which aims to advance OQY-3258 into global Phase 3 trials and build a differentiated ADC pipeline by leveraging their combined expertise.OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials:. -- A Phase 1a/1b clinical trial for patients with sol","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4195","BK4555","BK4585","TM","BK4211","ORR","VINC","BK4139","BK4588","PFS","BK4099"],"gpt_icon":0},{"id":"2506519597","title":"Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2506519597","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506519597?lang=en_us&edition=fundamental","pubTime":"2025-01-28 20:00","pubTimestamp":1738065600,"startTime":"0","endTime":"0","summary":"35% objective response rate  in second-line colorectal cancer  patients treated with sirexatamab  plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm. DKK1 levels highly correlated with clinical activity in CRC population. ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations. Preparations will begin for a registrational Phase 3 study in second-line CRC patients. DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations,but not the signal necessary to advance into Phase 3. CAMBRIDGE, Mass., Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab  in combination with bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer , and initial data from Part C of the DisTinGuish stud","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-initial-clinical-120000712.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-initial-clinical-120000712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRC","LU0054578231.USD","LU0053671581.USD","LU0266512127.USD","BK4195","BK4563","BK4543","LPTX","ORR","IE00BMPRXR70.SGD","BK4211","ITT","BK4113","BK4141","LU0348723411.USD","BK4585","LENZ","LU0456854461.SGD","BK4139","MSS","IE00BMPRXQ63.HKD","BK4505","BK4213","BK4161","BK4588","IE00BMPRXN33.USD","PFS"],"gpt_icon":1},{"id":"2506539108","title":"ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2506539108","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506539108?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:00","pubTimestamp":1738018800,"startTime":"0","endTime":"0","summary":"Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year. Approval brings AstraZeneca and Daiichi Sankyo’s ENHERTU to an earlier HR-positive treatment setting and broadens the patient population eligible for treatment with a HER2-directed therapy to those with HER2-ultralow disease. WILMINGTON, Del., January 27, 2025----AstraZeneca and Daiichi Sankyo’s ENHERTU  has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor -positive, HER2-low  or HER2-ultralow  breast cancer, as determined by a Food and Drug Administration -approved test, that has progressed on one or more endocrine therapies in the metastatic setting.The approval was granted by the FDA after securing Priority Review and Breakthrough Therapy Designation and was based on results from the DESTINY-Breast06 Phase III trial, which were presented at the 2024 A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-fam-trastuzumab-deruxtecan-nxki-230000535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2456880835.USD","BK4568","LU2417539215.USD","LU0320765992.SGD","BK4225","OS","PFS","AZN","BK4231","BK4585","LU0889565916.HKD","BK4080","BK4203","BK4195","LU2462157665.USD","BK4211","LU2236285917.USD","HR","LU1829250122.USD","BK4007","BK4588","ORR","BK4097","LU0109394709.USD","ADC"],"gpt_icon":0},{"id":"2506063589","title":"Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2506063589","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506063589?lang=en_us&edition=fundamental","pubTime":"2025-01-28 03:23","pubTimestamp":1738005795,"startTime":"0","endTime":"0","summary":"On Saturday, Pfizer Inc. revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi in combination with cetuximab  and mFOLFOX6  in patients with metastatic colorectal cancer  with aBRAF V600E mutation.At the time of this analysis, the Braftovi combination regimen demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate  compared to patients receiving chemotherapy with or without bevacizumab .Also Read: Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges. The results were presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancer Symposium  and were simultaneously published inNature Medicine.The estimated median duration of response was 13.9 months with Braftovi plus cetuximab and mFOLFOX6 and 11.1 months with chemotherapy with or without bevacizumab.Of patients on Braftovi plus cetuximab and mFOLFOX6, 22.4%  had a response lasting 12 months or longer, compared to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizers-conditionally-approved-braftovi-combo-192315424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","SG9999001176.SGD","LU0868494617.USD","LU0456855351.SGD","LU0122379950.USD","BK4581","LU0306806265.USD","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","SG9999001176.USD","BK4007","IE0002270589.USD","SG9999011175.SGD","LU1883839398.USD","BK4534","BK4097","LU0321505868.SGD","BK4211","PFE","SG9999013999.USD","SG9999002232.USD","BK4195","OS","IE00BLSP4239.USD","LU0225771236.USD","LU1023059063.AUD","BK4568","LU0170899867.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU0234572021.USD","PFS","LU1057294990.SGD","LU1894683264.USD","IE00BBT3K403.USD","BK4592","LU1894683348.USD","IE000M9KFDE8.USD","LU1066051498.USD","BK4585","IE00BLSP4452.SGD","BK4599","BK4550","ORR","IE00B19Z3B42.SGD","LU0225284248.USD","SG9999002224.SGD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2505971350","title":"Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2505971350","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505971350?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:30","pubTimestamp":1737635400,"startTime":"0","endTime":"0","summary":"Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025. Potential U.S. commercial launch in recurrent KRAS mutant LGSOC planned for mid-2025. RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress, with updated data expected in Q1 2025 to guide RP2D decision for trial expansion. VS-7375 is on track for U.S. IND filing in Q1 2025 with plans for a Phase 1/2a study in mid-2025. Cash position following recent debt and equity financing provides expected runway beyond potential FDA approval and helps to advance early-stage pipeline. BOSTON, January 23, 2025----Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for its novel clinical pipeline.On December 30, 2024, the U.S. Food and Drug Administration  accepted the Co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verastem-oncology-outlines-2025-strategic-123000167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VSTM","ORR","BK4139"],"gpt_icon":0},{"id":"2505414744","title":"Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2505414744","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505414744?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"Cohort A data to be presented in a poster session at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Data reported positive trend in overall survival, including 4 complete responses observed in the certepetide treatment group compared to none in placebo group. Data from Cohort B expected in the coming months, with full data from both cohorts to be reported thereafter. Cohort A of the ASCEND trial completed enrollment in the third quarter of 2023. The preliminary data from Cohort A demonstrate a median overall survival  of 12.68 months for the certepetide treated group, compared to 9.72 months for the placebo treated group. Despite a numerical trend in 6-month PFS favoring the certepet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lisata-therapeutics-reports-encouraging-preliminary-130000586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","PST","LSTA","LENZ","BK4124","BK4139","SMP"],"gpt_icon":0},{"id":"2505738151","title":"Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505738151","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505738151?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:05","pubTimestamp":1737497100,"startTime":"0","endTime":"0","summary":"27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/21/3013106/0/en/Xilio-Therapeutics-Announces-Initial-Phase-2-Data-for-Vilastobart-XTX101-a-Tumor-Activated-Anti-CTLA-4-in-Combination-with-Atezolizumab-in-Patients-with-Metastatic-Microsatellite-S.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011746.SGD","BK4139","BK4588","BK4108","LU0053666078.USD","AST","BK4548","ORR","IE00B12V2V27.USD","IE00BYQNZ168.SGD","BK4585","BK4565","LU2039709279.SGD","BK4599","BK4500","LENZ","BK4107","LU0359202008.SGD","BK4509","L","BK4008","BK4531","BK4563","LU1023057109.AUD","ALT","01698","BK4526","BK4535","IE00BYTNYN87.SGD","CEA","BK4552","BK4571","LU1878469433.USD","LU0359201612.USD","TME"],"gpt_icon":0},{"id":"2505213082","title":"Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2505213082","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505213082?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:00","pubTimestamp":1737460800,"startTime":"0","endTime":"0","summary":"– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters highlight the safety data, tolerability data, and antitumor efficac","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/21/3012498/0/en/Verrica-Pharmaceuticals-Announces-Presentation-of-Three-Posters-Featuring-Positive-Preliminary-Topline-Results-of-VP-315-for-the-Treatment-of-Basal-Cell-Carcinoma-at-the-2025-Winte.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4104","BK4567","BCC"],"gpt_icon":0},{"id":"2505234259","title":"Firstgroup and Virgin push back against state clampdown on open-access rail firms","url":"https://stock-news.laohu8.com/highlight/detail?id=2505234259","media":"cityam","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505234259?lang=en_us&edition=fundamental","pubTime":"2025-01-21 00:40","pubTimestamp":1737391237,"startTime":"0","endTime":"0","summary":"Open access is viewed as a success story by many in the railway industry for its ability to stimulate competition and demand. Firstgroup and Virgin are combining to push back against a government clampdown on some of the last private train firms operating the UK’s railway tracks.So-called open access is a lesser-used model in which firms shoulder commercial risk but take the entire share of any profit. It is viewed as a success story by many in the industry for its ability to boost competition, stimulate demand, and bring down fares. Since Firstgroup’s subsidiary Lumo launched in 2021, around 6m more passenger journeys have taken place on the East Coast Mainline than when it was operated solely by LNER.But services such as Lumo and Hull Trains are facing greater restrictions under Labour’s new transport secretary, Heidi Alexander, who has ordered the regulator, the Office of Rail and Road , to take a sterner stance when approving applications for new routes.","market":"fut","thumbnail":"https://www.cityam.com/wp-content/uploads/2024/05/lumo-1200-x-800.webp?w=286&h=161&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2024/05/lumo-1200-x-800.webp?w=286&h=161&crop=1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/firstgroup-and-virgin-push-back-against-state-clampdown-on-open-access-rail-firms/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ORR"],"gpt_icon":0},{"id":"2504164913","title":"FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER","url":"https://stock-news.laohu8.com/highlight/detail?id=2504164913","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504164913?lang=en_us&edition=fundamental","pubTime":"2025-01-17 22:01","pubTimestamp":1737122460,"startTime":"0","endTime":"0","summary":"Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC. \"Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and fewer than one in five people diagnosed with metastatic disease survive beyond five years after diagnosis,\" said Jay Bradner, M.D., executive vice president of Research and Development at Amgen.2 \"LUMAKRAS plus Vectibix offers a targeted, biomarker-driven combination therapy that helps delay disease progression more effectively than the investigated standard of care. This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer.\". TheKRASG12C mutation is present in approximately 3-5% of colorec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fda-approves-lumakras-sotorasib-combination-140100845.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-lumakras-sotorasib-combination-140100845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","LU2242652126.USD","BK4585","LU0289739699.SGD","BK4211","BK4533","BK4195","AST","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","AMGN","SOC","LU0456854461.SGD","BK4534","IE0002141913.USD","BK4599","FOR","BK4213","BK4566","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0320765992.SGD","PFS","BK4203","LU1983299246.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4097","BK4024","HR","LU0122379950.USD","ORR","SG9999001440.SGD","OS","BK4139","BK4581","PMR","LU1571399168.USD","LU0266512127.USD","IE00B2B36J28.USD","LU1061106388.HKD","CRC","LU0868494617.USD","BK4588","BK4225","LU1878469433.USD","LU1057294990.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2504547451","title":"CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2504547451","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504547451?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:00","pubTimestamp":1737115200,"startTime":"0","endTime":"0","summary":"Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone. First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US. WILMINGTON, Del., January 17, 2025----AstraZeneca’s CALQUENCE  in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma  who are ineligible for autologous hematopoietic stem cell transplantation.The approval was granted by the Food and Drug Administration  after securing Priority Review. It was based on results from the ECHO Phase III trial which were presented at the European Hematology Association 2024 Congress.Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: \"With today’s approval, CALQUENCE provides a critical new treatment option to mantle cell lymphoma patients in the US, with CALQUENCE proven to deliver nearly one and a h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calquence-acalabrutinib-plus-chemoimmunotherapy-approved-120000864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4106","LU0390134368.USD","HSCT","BK4139","LU0545562505.USD","LU2236285917.USD","AZN","IE0009354923.USD","LU1829250122.USD","BK4551","BNTX","LU2456880835.USD","PML","BK4568","BK4007","BK4548","BK4585","BK4535","BK4226","LU0109394709.USD","BK4588","LU0889565916.HKD","LU1228905540.USD","LU2417539215.USD","LU0320765992.SGD","LU1228905037.USD","IE0034235188.USD","BR","ORR","LU2462157665.USD"],"gpt_icon":0},{"id":"2503209990","title":"RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503209990","media":"CNW Group","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503209990?lang=en_us&edition=fundamental","pubTime":"2025-01-16 22:11","pubTimestamp":1737036660,"startTime":"0","endTime":"0","summary":"Phase 3 MARIPOSA-2 study showed RYBREVANT in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.1. TORONTO, Jan. 16, 2025 /CNW/ - Johnson & Johnson  announced today that Health Canada has issued a Notice of Compliance  for RYBREVANT  in combination with carboplatin and pemetrexed  for the treatment of patients with locally advanced or metastatic non-small cell lung cancer  with activating epidermal growth factor receptor  Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.1. \"A lung cancer diagnosis can be devastating. Thisapproval of RYBREVANTis welcome news for patients, offering hope against this difficult-to-treat disease and a chance to spend more quality time with their loved ones,\"says Shem Singh***, Executive Director, Lung Cancer Canada. \"Having this new therapeutic option underscores the importance of ongoing resear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rybrevant-plus-chemotherapy-approved-canada-141100584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","IE00B42XCP33.USD","IE00BGHQF631.EUR","BK4211","JNJ","BK4588","LU1066053197.SGD","LU1066051498.USD","BK4533","LU1674673428.USD","BK4007","IE0009355771.USD","BK4603","LU1066051811.HKD","LU1718418525.SGD","BK4187","LU0912757837.SGD","OS","IE00BVYPNW00.USD","NOC","LU0234570918.USD","LU0345769631.USD","IE0034235303.USD","LU1261432733.SGD","ORR","LU0345769128.USD","LU1280957306.USD","LU1988902786.USD","LU1032955483.USD","IE00B2B36J28.USD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","BK4592","LU1057294990.SGD","LU1221951046.USD","BK4195","LU0234572021.USD","IE00BVYPNV92.GBP","IE00BDGV0183.EUR","LU1506573853.SGD","LU1674673691.USD","BK4097","LU1894683264.USD","LU1066051225.USD","LU2112291526.USD","LU1894683348.USD","LU0203345920.USD","PFS","IE00BJT1NW94.SGD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":117,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}